Why Novo Nordisk Stock Plummeted Today

Novo Nordisk's shares dropped 7.2% after the company lowered its full-year sales growth guidance to 8-14% (from 13-21%) and operating profit guidance to 10-16% (from 16-24%), citing increased competitive pressure from U.S. compounders on its GLP-1 drugs, Wegovy and Ozempic. This guidance cut, despite management's optimism, prompted analyst downgrades from firms like Barclays and Bank of America, who view the threat as significant.

Analysis

Novo Nordisk (NVO) experienced a significant 7.2% single-day share price decline following a downward revision of its full-year financial guidance. The company now projects sales growth of 8% to 14%, a material reduction from the previous range of 13% to 21%, and has lowered its operating profit growth forecast to between 10% and 16% from a prior 16% to 24%. This revision is directly attributed to intensifying sales pressure on its blockbuster GLP-1 drugs, Wegovy and Ozempic, from U.S. compounders. A clear divergence has emerged between the company's management, which maintains an optimistic tone regarding the competitive threat, and Wall Street's assessment. This skepticism is evidenced by downgrades from Barclays to 'equal-weight' and Bank of America to 'neutral,' indicating a belief that the competitive risks are more significant than acknowledged. The market sell-off has compressed the company's valuation, pushing its price-to-earnings ratio to one of its lowest levels in nearly 30 years and its lowest point since before 2020.

Key Decisions for Investors

• Investors should closely monitor the impact of compounder competition on Wegovy and Ozempic sales in subsequent quarters, as this is the primary driver of the revised guidance and recent analyst downgrades.
• The stock's valuation, now at a multi-decade low P/E ratio, presents a classic value-versus-momentum dilemma; any potential position should weigh this historically low valuation against the clear negative sentiment and near-term operational headwinds.
• Scrutinize management's commentary in future earnings calls to assess whether their optimistic view on the competitive landscape aligns with reported sales figures, as a continued disconnect could signal further downside risk and a loss of credibility.